Streamlining AAV Characterization With Automated Mass Photometry

Published on: 


Webinar Date/Time: Thu, Dec 1, 2022 11:00 AM EST

Say hello to the SamuxMP Auto, a cutting-edge mass photometer that can streamline your AAV characterization process. With this instrument, you can rapidly and autonomously measure empty/full capsid ratios for multiple AAV samples of any serotype with low sample consumption, speeding up your analytical workflows and increasing productivity.

Register Free:

Event Overview:

While gene therapies based on adeno-associated virus (AAV) vectors appear highly promising, there is an urgent need for improved AAV analytics. AAV production processes generate empty capsids, which can complicate vector purification and reduce product safety and quality. Mass photometry is an ideal analytics technology for labs working with AAVs, as it enables users to precisely measure the empty/full capsid ratio for AAVs of any serotype using very low sample volumes and concentrations, and with minimal sample preparation.

This webinar will discuss how mass photometry can be used to characterize AAV capsids and provide vital insights for manufacturing process development. It will also introduce the SamuxMP Auto, Refeyn’s new automated mass photometer. The SamuxMP Auto builds up on the strengths of mass photometry, streamlining the AAV characterization process from sample preparation to data capture and making process development for AAV-based therapeutics significantly more efficient.

Key Learning Objectives

  • Understand the challenges of AAV characterization
  • Explore the benefits of mass photometry to quantify the ratio of empty-full AAV capsids of any serotype
  • Learn how the SamuxMP Auto can streamline AAV characterization processes


Svea Cheeseman
Director of Product Management
Cell and Gene Therapy

Svea Cheeseman is the Director of Product Management for Cell and Gene Therapy at Refeyn, responsible for products targeted for the Biopharma industry. She holds a PhD in single-molecule biophysics and has 5 years’ experience in the Biopharma industry. She has a keen interest in pushing the boundaries of biomolecular analysis to eventually enable real-time release of biomolecular drugs.

Register Free: